



**VIRTUAL/TELECONFERENCE
CONTROLLED SUBSTANCES BOARD
Virtual, 4822 Madison Yards Way, Madison
Contact: Tom Ryan (608) 266-2112
May 12, 2023**

The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the actions and deliberations of the Board.

AGENDA

9:30 A.M.

OPEN SESSION – CALL TO ORDER – ROLL CALL

A. Adoption of Agenda

B. Approval of Minutes March 10, 2023

C. Reminders: Conflicts of Interests, Scheduling Concerns

D. Introductions, Announcements and Recognition

E. Administrative Matters – Discussion and Consideration

- 1) Department, Staff, and Board Updates
- 2) Board Members – Term Expiration Dates
 - a. Alton, Troy – Dentistry Examining Board Representative
 - b. Barman, Subhadeep – 5/1/2019
 - c. Bellay, Yvonne – DATCP Representative
 - d. Bloom, Alan – 5/1/2020
 - e. Englebert, Doug – DHS Representative
 - f. Koresch, Sandy – AAG Representative
 - g. Weinman, Robert – Board of Nursing Representative
 - h. Weitekamp, John – Pharmacy Examining Board Representative
 - i. Yerby, Lemuel – Medical Examining Board Representative
- 3) Alternates
 - a. Bistan, Matthew – Dentistry Examining Board Representative
 - b. Ferguson, Kris – Medical Examining Board Representative
 - c. McFarland, Rosalyn – Board of Nursing Representative
 - d. Parish, Michael – Medical Examining Board Representative
 - e. Wasserman, Sheldon – Medical Examining Board Representative
 - f. Zentz, Emily – Board of Nursing Representative

F. Administrative Rule Matters – Discussion and Consideration

- 1) Adoption Order:
 - a. CSB 2.78, Relating to Scheduling Crotonyl Fentanyl
 - b. CSB 2.79, Relating to Scheduling Remimazolam
 - c. CSB 2.81, Relating to Scheduling Bupropion

- d. CSB 2.82, Relating to Scheduling Serdexmethylphenidate
- e. CSB 2.83, Relating to Scheduling 10 Fentanyl Related Substances
- f. CSB 2.84, Relating to Scheduling Alfaxalone
- g. CSB 2.85, Relating to Excluding 6-beta-naltrexol
- h. CSB 2.86, Relating to Scheduling Fospropofol
- i. CSB 2.87, Relating to Scheduling Embutramide
- j. CSB 2.88, Relating to Scheduling Lacosamide
- k. CSB 2.89, Relating to Scheduling Perampanel
- l. CSB 2.90, Relating to Transferring 1-phenycyclohexylamine and 1-piperidinoocyclohexanecarbonitrile, Immediate Precursors to Phencyclidine, Also Known as PCP
- m. CSB 2.91, Relating to Scheduling 4,4'-Dimethylaminorex
- 2) Scope Statements
 - a. CSB 2.96, Relating to Scheduling Amineptine
 - b. CSB 2.97, Relating to Scheduling Zipeprol
 - c. CSB 2.98, Relating to Excluding [18 F] FP-CIT
 - d. CSB 2.99, Relating to Scheduling Mesocarb
 - e. CSB 4, Relating to Monitored Prescription Drug History Reports
- 3) Pending and Possible Rulemaking Projects
 - a. Rule Projects Chart

G. Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration

- 1) WI ePDMP Operations
 - a. CSB PDMP Report Q1 2023
 - b. Recent and Upcoming Releases
 - c. Status of Grant Projects:
 - a. FY 2020 Harold Rogers Prescription Drug Monitoring Program
 - b. FY 2021 Harold Rogers Prescription Drug Monitoring Program
 - a. EHR Integration Status
 - c. FY 2022 Harold Rogers Prescription Drug Monitoring Program
- 2) WI ePDMP Outreach

H. Board Member Reports – Discussion and Consideration

- 1) Medical Examining Board
- 2) Dentistry Examining Board
- 3) Board of Nursing
- 4) Pharmacy Examining Board

I. Liaison Reports

J. Report from the Referral Criteria Work Group – Discussion and Consideration

K. Deliberation on Special Use Authorizations – Discussion and Consideration

L. Discussion and Consideration of Items Received After Preparation of the Agenda

- 1) Introductions, Announcements, and Recognition
- 2) Administrative Matters
- 3) Election of Officers
- 4) Appointment of Liaisons and Alternates
- 5) Delegation of Authorities
- 6) Informational Items

- 7) Division of Legal Services and Compliance (DLSC) Matters
- 8) Education and Examination Matters
- 9) Credentialing Matters
- 10) Practice Matters
- 11) Legislative and Administrative Rule Matters
- 12) Liaison Reports
- 13) Public Health Emergencies
- 14) Appearances from Requests Received or Renewed
- 15) Speaking Engagements, Travel, or Public Relations Requests, and Reports
- 16) Consulting with Legal Counsel

M. Public Comments

CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).

N. Deliberation on Special Use Authorizations – Discussion and Consideration

O. Consulting with Legal Counsel

RECONVENE TO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION

P. Vote on Items Considered or Deliberated Upon in Closed Session if Voting is Appropriate

Q. Open Session Items Noticed Above Not Completed in the Initial Open Session

ADJOURNMENT

NEXT MEETING: JULY 14, 2023

MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held virtually unless otherwise indicated. In-person meetings are typically conducted at 4822 Madison Yards Way, Madison, Wisconsin, unless an alternative location is listed on the meeting notice. In order to confirm a meeting or to request a complete copy of the board's agenda, please visit the Department website at <https://dps.wi.gov>. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of disciplinary hearings may be changed by the examiner for the convenience of the parties. Requests for interpreters for the hard of hearing, or other accommodations, are considered upon request by contacting the Affirmative Action Officer, or the Meeting Staff at 608-267-7213.